Recent insight into the balance of self-tolerance and autoaggression has raised interest in using human regulatory T (Treg) cells for adoptive immunotherapy of unlimited autoimmune diseases including type-1 diabetes, rhematoid arthritis and multiple sclerosis. The therapeutic use of Treg cells, however, is so far hampered by the inefficiency of current protocols in making them accessible for genetic manipulations. We report here that TCR/CD3 stimulation that is accompanied by extensive CD28 costimulation makes human Treg cells susceptible to retroviral gene transfer ex vivo while preserving their properties in vitro and in vivo. 
Introduction
The balance between immunological self-tolerance and auto-aggression depends on the appropriate ratio of effector T cells and CD4 + CD25 high regulatory T (Treg) cells, the latter control ongoing T-cell responses and T-cell hemostasis by the repression of effector T-cell proliferation. 1, 2 Their capacity to mediate tolerance has raised interest in using human Treg cells for the adoptive immunotherapy of disbalanced immune reactions based on insufficient repressive capacities including type-1 diabetes, 3 multiple sclerosis, 4 rheumatoid arthitis 5 or transplant rejection. 6 Despite a plethora of therapeutic options, genetic manipulation and translation to the clinic are so far hampered by the proliferative anergy of human Treg cells under standard ex vivo conditions and their inaccessibility for genetic manipulations. Current attempts to induce proliferation of human Treg cells make use of stimulator cells in presence of interleukin (IL)-2, including dendritic cells, [7] [8] [9] allogeneic lymphoblastoid feeder cells 10 or artificial antigen-presenting cells 9, 11 with or without feeder cells. 12 All procedures, however, suffer from a number of insufficiencies preventing efficient genetic manipulation of human Treg cells.
By systematic exploring the stimulatory conditions, we here revealed that human CD4 + CD25 high FoxP3 + Treg cells require strong TCR/CD3z engagement simultaneously with an extensive CD28 costimulatory signal to become susceptible for retroviral gene transfer. It is noteworthy that after genetic manipulation, Treg cells execute their effector functions in an antigen-specific manner and preserve their repressive capacities in vivo. The procedure described here allows to generate 'designer Treg cells' by genetic modification, which are specifically activated and capable to repress an ongoing immune response, leading to efficient immune repression in vivo. This is exemplarily shown by engineered Treg cells, which express a chimeric immunoreceptor to booster Treg cell-mediated repression upon site-specific encounter of a pre-defined antigen. The strategy thereby opens new possibilities for an orchestrated immune repression by adoptive transfer of genetically modified Treg cells.
Results

Human CD4
+ CD25 high Treg cells were isolated to high purities from the peripheral blood by magnetic cell sorting procedures (Figure 1a (Figures 2a and b) . CD3/CD28-stimulated CD4 + CD25 À T cells secrete high amounts of IFN-g and IL-2 but low amounts of IL-10, whereas Treg cells lacked IL-2 secretion but secreted high amounts of IL-10 (Figures 2c-h ). As Treg cells are proned to high spontaneous apoptosis, 13 we tested whether CD3/CD28 costimulation under these conditions impact the frequency of apoptotic cell death of Treg cells in vitro. (Figure 4 ). We now asked whether genetically modified Treg cells are functionally activated by immunoreceptor signaling in vitro and in vivo. To stimulate specifically by immunoreceptor, engineered Treg cells were incubated in vitro with the anti-idiotypic antibody BW2064 directed against the CEA-binding domain of the immunoreceptor as surrogate antigen. As summarized in Figure 5 , engineered Treg cells were specifically induced to proliferate upon immunoreceptor binding, whereas non-modified Treg cells were not. Engineered Treg cells moreover secreted high amounts of IL-10 but no IL-2 upon immunoreceptor activation, whereas engineered CD4 + CD25 À T cells secreted IFN-g and IL-2, but only minor amounts of IL-10 ( Figure 5 ). Treg cell activation is specifically mediated by the transduced immunoreceptor, as incubation of engineered Treg cells with an antibody of irrelevant specificity did not induce cytokine secretion. The set of induced cytokines upon immunoreceptor triggering of engineered Treg cells is identical to that of non-modified Treg cells upon physiological CD3 and CD28 stimulation using agonistic monoclonal antibodies (mAbs) (cf. Figure 2) , indicating functional activation of ex vivo genetically engineered Treg cells.
To explore whether engineered Treg cells are specifically activated to execute their effector functions in vivo, we used tumor growth in the presence of an ongoing antitumor cytolytic T-cell (CTL) response. Subcutaneous 
Discussion
Despite the mechanisms of suppression remain enigmatic in detail, Treg cells are thought to be maintained and activated in the periphery by recognizing selfantigens. Accordingly, the T-cell receptor repertoire of Treg cells mediates major histocompatibility complex class II interactions with higher efficiency than those of CD4 + CD25 À T cells. 14 The determination of self-antigens that can be used for antigen-specific expansion of ex vivo isolated Treg cells, however, remains extremely difficult. Antigen-specific Treg cells, on the other hand, are of growing interest due to their potential to limit an ongoing cellular immune response and to proliferate, to persist and to execute their repressor functions at the site of the ongoing immune reaction. Antigen-specific Treg cells in sufficient quantities and with defined specificity would open novel therapeutic options in a variety of chronic inflammatory and autoimmune diseases.
To overcome the current limitations in the isolation of Treg cells with known specificity, we here exploid a strategy to graft pre-defined specificity on Treg cells by expression of a recombinant immunoreceptor on the cell surface. The immunoreceptor has extracellularly an antibody-derived, major histocompatibility complex independent antigen-binding domain and intracellularly a combined, strong CD3z-CD28 cosignaling domain. Engineered Treg cells with recombinant immunoreceptor are aimed at repressing the ongoing inflammatory immune response in an antigen-specific manner.
We Figure  2) . CD4 + CD25 high Treg cells require strong CD28 costimulation in addition to CD3/TCR signaling to initiate proliferation, whereas CD4 + CD25 À T cells can also proliferate without the need of CD28 costimulation but CD3 stimulation in the presence of IL-2. The strategy of genetically engineering 'designer' Treg cells implies to target antigen-specific Treg cells toward sites of inflammation to repress an ongoing autoimmune reaction in a locally restricted manner. As an example, intestinal bowel disease is an autoimmune disease that is characterized by a non-limited inflammation in the gut and elevated CEA expression in the inflammatory lesion. 16, 17 Due to the chronic inflammatory process, intestinal bowel disease is thought to be a precancerosis with the therapeutic need to repress the ongoing inflammatory process. The latter is currently aimed to be achieved by the systemic application of non-steroid antiphlogistic drugs, however, with remarkable systemic site effects. In patients suffering from active intestinal + Treg cells in both the inflammatory lesion and the periphery is decreased. 18 Adoptive transfer of antigen-specific Treg cells in an animal model of chronic colitis was recently demonstrated to efficiently suppress the circle of inflammatory reactions. 19 Adoptive transfer of engineered, CEA-specific CD4 + CD25 + Treg cells from the peripheral blood as used in this study aims to result in site-specific activation of Treg cells, to drive their amplification and persistence within the inflammatory lesion and to locally repress the immune reactions as long as CEA-specific Treg cells are reactivated by binding to CEA + colon epithelial cells. We here provide a strategy to redirect human Treg cells from the periphery in an antigen-specific manner, leading to their site-specific persistance and repression of an ongoing immune response in vivo, which is more effective than mediated by Treg cells without antigen-triggered activation.
Materials and methods
Cell lines and reagents
HEK-293T cells are human embryonic kidney cells that express the SV40 large T antigen. 20 The murine fibrosarcoma cell line that was transfected to express human CEA was previously described. 21 The hybridoma cell line OKT3, that produces the anti-CD3 mAb OKT3, was obtained from ATCC, Rockville, MD, USA (ATCC CRL 8001). The hybridoma cell line that produces the anti-CD28 mAb 15E8 22 was a kind gift from R van Lier, Academic Medical Center, Amsterdam, The Netherlands. MAbs were affinity purified from hybridoma supernatants using an agarose immobilized goat antimouse IgG1 (Sigma, Deisenhofen, Germany) or a sepharose (BD Bioscience, Freiburg, Germany) immobilized goat anti-mouse IgG2a antibody (Southern Biotechnology, Birmingham, AL, USA). All cell lines were cultured in RPMI 1640 medium, 10% (v/v) fetal calf serum (FCS) (all from Life Technologies, Paisly, UK). À and CD4 + CD25 + T cells were identified by two-color immunofluorescence using fluorescein isothiocyanate-conjugated anti-CD4 (Dako) and PE-conjugated anti-CD25 (Miltenyi Biotec) mAbs, respectively. À T cells were further cultivated in RPMI 1640 medium, 10% (v/v) FCS supplemented with IL-2 (400 U ml À1 ). Before in vitro assays, the cells were washed three times and rested for 24 h in RPMI 1640 medium, 10% (v/v) FCS without additional stimulation.
Generation and expression of recombinant anti-CEA immunoreceptors
The generation of the retroviral expression cassettes for the recombinant anti-CEA immunoreceptor BW431/26-Fc-CD28-z immunoreceptor was previously described in detail. 23 Retroviral transduction of T cells to express the recombinant immunoreceptor was also described in detail elsewhere. 20, [24] [25] [26] [27] Transduction of Treg cells was performed accordingly with modifications as follows: Treg cells were activated as described above and cocultivated for 48 h with HEK-293T retrovirus producer cells in X-Vivo15 medium, 10% (v/v) FCS supplemented with IL-2 (1000 U ml
À1
) and IL-15 (1 ng ml
).
Immunofluorescenence and FACS analyses
T cells that express the recombinant immunoreceptor were identified using a PE-conjugated F(ab 0 ) 2 antihuman IgG1 antibody (0.5 mg ml ). T cells grafted with the chimeric anti-CEA-CD28-z immunoreceptor were incubated in precoated microtiter plates (1 Â 10 4 receptor grafted T-cells per well) and cell proliferation and cytokine secretion were determined as described above.
Suppressor assay
CD4
+ CD25 À responder T cells were labeled with CFSE (Invitrogen, Karlsruhe, Germany) essentially as described. 28 Briefly, cells (1 Â Tumor volume was daily monitored. Statistical analysis was performed using the paired Student's t-test.
